Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Bladder Cancer

Free Subscription 13.03.2023 1 Acta Biomed 1 Adv Radiat Oncol 1 Ann Surg Oncol 1 BJU Int 2 BMC Bioinformatics 1 BMC Urol 1 BMJ Open 1 Br J Radiol 1 Bull Exp Biol Med 1 Cancer Causes Control 2 Cancer Cytopathol 2 Cancer Sci 1 Cell 1 Cell Biosci 1 Cell Oncol (Dordr) 4 Clin Genitourin Cancer 1 Comput Methods Programs Biomed 1 Curr Oncol Rep 1 Curr Opin Urol 3 Eur Urol Oncol 1 Eur Urol Open Sci 1 Front Oncol 2 Heliyon 1 IJU Case Rep 1 In Vivo 1 Int J Cancer 1 Int J Gen Med 2 Int J Mol Sci 4 Int J Urol 1 Int Urol Nephrol 1 Investig Clin Urol 1 J Cancer Res Clin Oncol 1 J Cannabis Res 1 J Clin Oncol 1 J Med Econ 1 J Pathol 1 J Postgrad Med 2 J Proteomics 1 J Ultrasound Med 1 J Urol 1 J Vet Diagn Invest 2 Jpn J Clin Oncol 1 Lab Invest 1 Lancet Oncol 1 Med Clin (Barc) 1 Med Lett Drugs Ther 1 Med Oncol 1 Nihon Ronen Igakkai Zasshi 1 Nucleus 1 Oncogene 1 Pharmacoeconomics 1 PLoS One 1 Prog Urol 2 Sci Rep 5 Urol Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Biomed

1. PASSALACQUA MI, Squeri A, Sciume C, Ieni A, et al
   Enfortumab Vedotin in metastatic bladder cancer: a case report of durable clinical efficacy in a pretreated patient.
   Acta Biomed. 2023;94.
   PubMed         Abstract available
   
   

   
   Adv Radiat Oncol

2. YAMAMOTO Y, Kawashima A, Morishima T, Uemura T, et al
   Comparative Effectiveness of Radiation Versus Radical Cystectomy for Localized Muscle-Invasive Bladder Cancer.
   Adv Radiat Oncol. 2022;8:101157.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. YANAGISAWA T, Matsukawa A, Iwatani K, Sato S, et al
   En Bloc Resection Versus Conventional TURBT for T1HG Bladder Cancer: A Propensity Score-Matched Analysis.
   Ann Surg Oncol. 2023 Mar 10. doi: 10.1245/s10434-023-13227.
   PubMed         Abstract available
   
   

   
   BJU Int

4. BESIROGLU H
   Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?
   BJU Int. 2023 Mar 10. doi: 10.1111/bju.16005.
   PubMed        
   
   

   
   BMC Bioinformatics

5. CIARAMELLA A, Di Nardo E, Terracciano D, Conte L, et al
   A new biomarker panel of ultraconserved long non-coding RNAs for bladder cancer prognosis by a machine learning based methodology.
   BMC Bioinformatics. 2023;23.
   PubMed         Abstract available
   
   
6. AMEEN YA, Badary DM, Abonnoor AEI, Hussain KF, et al
   Which data subset should be augmented for deep learning? a simulation study using urothelial cell carcinoma histopathology images.
   BMC Bioinformatics. 2023;24:75.
   PubMed         Abstract available
   
   

   
   BMC Urol

7. ZENG SP, Sun YF, Ye JB, Zeng K, et al
   Transurethral en bloc resection of a bladder perivascular epithelioid cell tumor (PEComa): a case report.
   BMC Urol. 2023;23:28.
   PubMed         Abstract available
   
   

   
   BMJ Open

8. AKDEMIR E, Sweegers MG, Vrieling A, Rundqvist H, et al
   EffectiveNess of a multimodal preHAbilitation program in patieNts with bladder canCEr undergoing radical cystectomy: protocol of the ENHANCE multicentre randomised controlled trial.
   BMJ Open. 2023;13:e071304.
   PubMed         Abstract available
   
   

   
   Br J Radiol

9. FAN X, Yu H, Ni X, Chen G, et al
   Systematic radiomics analysis based on multiparameter MRI to preoperatively predict the expression of Ki67 and histological grade in patients with bladder cancer.
   Br J Radiol. 2023 Mar 8:20221086. doi: 10.1259/bjr.20221086.
   PubMed         Abstract available
   
   

   
   Bull Exp Biol Med

10. ZUKOV RA, Savchenko AA, Slepov EV, Semenov EV, et al
    Phenotype of Urine Sediment Cells in Patients with Bladder Cancer.
    Bull Exp Biol Med. 2023 Mar 9. doi: 10.1007/s10517-023-05732.
    PubMed         Abstract available
    
    

    
    Cancer Causes Control

11. SHU TD, Schumacher FR, Conroy B, Ponsky L, et al
    Disparities in cause-specific mortality by race and sex among bladder cancer patients from the SEER database.
    Cancer Causes Control. 2023 Mar 8. doi: 10.1007/s10552-023-01679.
    PubMed         Abstract available
    
    

    
    Cancer Cytopathol

12. CHEN Y, Fu J, Li Z, Chen Q, et al
    Cutoff values of PD-L1 expression in urinary cytology samples for predicting response to immune checkpoint inhibitor therapy in upper urinary tract urothelial carcinoma.
    Cancer Cytopathol. 2023;131:179-187.
    PubMed         Abstract available
    
    
13. PIERCONTI F, Rossi ED, Cenci T, Carlino A, et al
    DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group.
    Cancer Cytopathol. 2023;131:158-164.
    PubMed         Abstract available
    
    

    
    Cancer Sci

14. QIWEI C, Jiajun S, Cheng L, Shengbo H, et al
    Comparison between renal pelvic and ureteral tumors in muscle-invasive upper tract urothelial carcinoma.
    Cancer Sci. 2023;114:984-994.
    PubMed         Abstract available
    
    
15. MIYAKE M, Oda Y, Owari T, Iida K, et al
    Probiotics enhances anti-tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer.
    Cancer Sci. 2023;114:1118-1130.
    PubMed         Abstract available
    
    

    
    Cell

16. HERZOG RW, Suzuki M
    Adenoviral gene therapy for bladder cancer.
    Cell. 2023;186:893.
    PubMed         Abstract available
    
    

    
    Cell Biosci

17. CHEN L, Dong W, Zhou M, Yang C, et al
    PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression.
    Cell Biosci. 2023;13:45.
    PubMed         Abstract available
    
    

    
    Cell Oncol (Dordr)

18. JIN D, Qian L, Xia J, Zhang R, et al
    In vivo detection demonstrates circulating tumor cell reduction instead of baseline number has prognostic value in bladder cancer patients receiving neoadjuvant chemotherapy.
    Cell Oncol (Dordr). 2023 Mar 6. doi: 10.1007/s13402-023-00785.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

19. MARANDINO L, Raggi D, Calareso G, Alessi A, et al
    Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial.
    Clin Genitourin Cancer. 2021;19:457-465.
    PubMed         Abstract available
    
    
20. POND GR, Agarwal A, Ornstein M, Garcia J, et al
    Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors.
    Clin Genitourin Cancer. 2021;19:425-433.
    PubMed         Abstract available
    
    
21. STOKKEL LE, Stokkel MPM, Donswijk ML, Lahaye MJ, et al
    The Diagnostic Value of FDG-PET/CT for Urachal Cancer.
    Clin Genitourin Cancer. 2021;19:373-380.
    PubMed         Abstract available
    
    
22. RUNDO F, Bersanelli M, Urzia V, Friedlaender A, et al
    Three-Dimensional Deep Noninvasive Radiomics for the Prediction of Disease Control in Patients With Metastatic Urothelial Carcinoma treated With Immunotherapy.
    Clin Genitourin Cancer. 2021;19:396-404.
    PubMed         Abstract available
    
    

    
    Comput Methods Programs Biomed

23. ANDRIKOS I, Stefanou K, Bellos C, Stergios G, et al
    EDIT Software: A tool for the semi-automatic 3D reconstruction of bladder cancer and urinary bladder of animal models.
    Comput Methods Programs Biomed. 2023;232:107448.
    PubMed         Abstract available
    
    

    
    Curr Oncol Rep

24. COCKRELL DC, Rose TL
    Current Status of Perioperative Therapy in Muscle-Invasive Bladder Cancer and Future Directions.
    Curr Oncol Rep. 2023 Mar 10. doi: 10.1007/s11912-023-01390.
    PubMed         Abstract available
    
    

    
    Curr Opin Urol

25. MUIN D, Laukhtina E, Hacker M, Shariat SF, et al
    PET in bladder cancer imaging.
    Curr Opin Urol. 2023 Mar 7. doi: 10.1097/MOU.0000000000001090.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

26. ST-LAURENT MP, Suderman J, Black PC
    Where To Draw the Line: Stratifying Risk for High-grade Ta Bladder Cancer.
    Eur Urol Oncol. 2023 Mar 3:S2588-9311(23)00035-4. doi: 10.1016/j.euo.2023.
    PubMed        
    
    
27. BUKAVINA L, Isali I, Ginwala R, Sindhani M, et al
    Global Meta-analysis of Urine Microbiome: Colonization of Polycyclic Aromatic Hydrocarbon-degrading Bacteria Among Bladder Cancer Patients.
    Eur Urol Oncol. 2023 Mar 1:S2588-9311(23)00036-6. doi: 10.1016/j.euo.2023.
    PubMed         Abstract available
    
    
28. CARAMELO B, Zagorac S, Corral S, Marques M, et al
    Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.
    Eur Urol Oncol. 2023 Mar 6:S2588-9311(23)00043-3. doi: 10.1016/j.euo.2023.
    PubMed         Abstract available
    
    

    
    Eur Urol Open Sci

29. COLLACOTT H, Krucien N, Heidenreich S, Catto JWF, et al
    Patient Preferences for Treatment of Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: A Cross-country Choice Experiment.
    Eur Urol Open Sci. 2023;49:92-99.
    PubMed         Abstract available
    
    

    
    Front Oncol

30. WANG H, Li J, Zi X, Yuan X, et al
    Comprehensive analysis of cuproptosis-related genes on bladder cancer prognosis, tumor microenvironment invasion, and drug sensitivity.
    Front Oncol. 2023;13:1116305.
    PubMed         Abstract available
    
    

    
    Heliyon

31. WU Y, Xu Y, He S, Li Y, et al
    Cytoskeleton regulator RNA expression on cancer-associated fibroblasts is associated with prognosis and immunotherapy response in bladder cancer.
    Heliyon. 2023;9:e13707.
    PubMed         Abstract available
    
    
32. LI T, Jiang N, Bai Y, Liu T, et al
    Prediction of immune infiltration and prognosis for patients with urothelial bladder cancer based on the DNA damage repair-related genes signature.
    Heliyon. 2023;9:e13661.
    PubMed         Abstract available
    
    

    
    IJU Case Rep

33. YOSHIOKA F, Kato T, Shima Y, Hatano K, et al
    Drug-induced interstitial pneumonia after intravesical Bacillus Calmette-Guerin administration for bladder cancer with scleroderma.
    IJU Case Rep. 2023;6:133-136.
    PubMed         Abstract available
    
    

    
    In Vivo

34. NAGAHISA C, Iizuka J, Kobari Y, Minoda R, et al
    Efficacy of Combined Pembrolizumab and Pelvic Radiotherapy for Bladder Cancer With Rectal Metastases.
    In Vivo. 2023;37:912-915.
    PubMed         Abstract available
    
    

    
    Int J Cancer

35. HIEN TT, Ambite I, Wan MLY, Cavalera M, et al
    Long-term prevention of bladder cancer progression by alpha1-oleate alone or in combination with chemotherapy.
    Int J Cancer. 2023 Mar 9. doi: 10.1002/ijc.34500.
    PubMed         Abstract available
    
    

    
    Int J Gen Med

36. CHEN R, Jiang M, Hu B, Fu B, et al
    Comprehensive Analysis of the Expression, Prognosis, and Biological Significance of PLOD Family in Bladder Cancer.
    Int J Gen Med. 2023;16:707-722.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

37. BLINOVA E, Samishina E, Deryabina O, Blinov D, et al
    Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma.
    Int J Mol Sci. 2021;22:9856.
    PubMed         Abstract available
    
    
38. LEE HW, Seo HK
    Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment.
    Int J Mol Sci. 2021;22:9526.
    PubMed         Abstract available
    
    

    
    Int J Urol

39. MIYAKE M, Oda Y, Nishimura N, Shimizu T, et al
    Chemotherapy with gemcitabine and cisplatin downregulates tumor expression level of nectin-4 in a syngeneic model of murine MBT2 urothelial cancer cell line and C3H mice.
    Int J Urol. 2023;30:328-330.
    PubMed        
    
    
40. MOEEN AM
    Editorial Comment on Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter-related bladder discomfort in TURBT: A randomized, double-blind, controlled trial.
    Int J Urol. 2023;30:270-271.
    PubMed        
    
    
41. CHEN W, Yokoyama M, Kobayashi M, Fan B, et al
    Trends of radical cystectomy and comparisons of surgical outcomes among surgical approaches focusing on robot-assisted radical cystectomy: A Japanese nationwide database study.
    Int J Urol. 2023;30:258-263.
    PubMed         Abstract available
    
    
42. SINGH A, Kayina CA, Naik N, Ganesh V, et al
    Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter related bladder discomfort in transurethral resection of bladder tumors: A randomized, double blind, controlled trial.
    Int J Urol. 2023;30:264-270.
    PubMed         Abstract available
    
    

    
    Int Urol Nephrol

43. GRIZZI F, Hegazi MAAA, Taverna G
    Letter to the editor re: "assessing bladder cancer prognosis through circulating tumor cell analysis and Ki-67 measurement".
    Int Urol Nephrol. 2023 Mar 3. doi: 10.1007/s11255-023-03538.
    PubMed        
    
    

    
    Investig Clin Urol

44. JEONG SH, Ku JH
    Treatment strategies for the Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.
    Investig Clin Urol. 2023;64:103-106.
    PubMed        
    
    

    
    J Cancer Res Clin Oncol

45. LEE Y, Kim YS, Hong B, Cho YM, et al
    Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
    J Cancer Res Clin Oncol. 2021;147:3421-3429.
    PubMed         Abstract available
    
    

    
    J Cannabis Res

46. WHYNOT EG, Tomko AM, Dupre DJ
    Anticancer properties of cannabidiol and Delta(9)-tetrahydrocannabinol and synergistic effects with gemcitabine and cisplatin in bladder cancer cell lines.
    J Cannabis Res. 2023;5:7.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

47. COLEMAN JA, Yip W, Wong NC, Sjoberg DD, et al
    Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.
    J Clin Oncol. 2023;41:1618-1625.
    PubMed         Abstract available
    
    

    
    J Med Econ

48. GRABE-HEYNE K, Henne C, Odeyemi I, Pohlmann J, et al
    Evaluating the cost-utility of intravesical bacillus calmette-guerin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    J Med Econ. 2023 Mar 10:1-19. doi: 10.1080/13696998.2023.2189860.
    PubMed         Abstract available
    
    

    
    J Pathol

49. FONTUGNE J, Wong J, Cabel L, Neyret-Kahn H, et al
    Progression-associated molecular changes in basal/squamous and sarcomatoid bladder carcinogenesis.
    J Pathol. 2023;259:455-467.
    PubMed         Abstract available
    
    

    
    J Postgrad Med

50. AGNIHOTRI MA, Sathe PA
    Coexistent urothelial papilloma and ureteric calculus in an 8-year-old child: A rare co-occurrence.
    J Postgrad Med. 2021;67:182-183.
    PubMed        
    
    

    
    J Proteomics

51. LOPEZ-CORTES R, Gomez BB, Vazquez-Estevez S, Perez-Fentes D, et al
    Blood-based protein biomarkers in bladder urothelial tumors.
    J Proteomics. 2021;247:104329.
    PubMed         Abstract available
    
    
52. CARVALHO LB, Martinez JLC, Lodeiro C, Bento R, et al
    Biochemical network analysis of protein-protein interactions to follow-up T1 bladder cancer patients.
    J Proteomics. 2023 Mar 2:104865. doi: 10.1016/j.jprot.2023.104865.
    PubMed         Abstract available
    
    

    
    J Ultrasound Med

53. HU X, Sun C, Ren X, Ge S, et al
    Contrast-enhanced Ultrasound Combined With Elastography for the Evaluation of Muscle-invasive Bladder Cancer in Rats.
    J Ultrasound Med. 2023 Mar 10. doi: 10.1002/jum.16216.
    PubMed         Abstract available
    
    

    
    J Urol

54. PENG CK, Sung WW, Chen SL
    Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
    J Urol. 2023 Mar 9:101097JU0000000000003407. doi: 10.1097/JU.0000000000003407.
    PubMed        
    
    

    
    J Vet Diagn Invest

55. SETYO LC, Donahoe SL, Shearer PL, Wang P, et al
    Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-beta, and CDK4 in canine urothelial carcinoma.
    J Vet Diagn Invest. 2023;35:109-115.
    PubMed         Abstract available
    
    

    
    Jpn J Clin Oncol

56. SEKINE Y, Iwasaki Y, Hakozaki N, Endo M, et al
    Prevalence and risk estimation of cancer-predisposing genes for upper urinary tract urothelial carcinoma in Japanese.
    Jpn J Clin Oncol. 2022;52:1441-1445.
    PubMed         Abstract available
    
    
57. MIYAKE M, Shimizu T, Oda Y, Tachibana A, et al
    Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.
    Jpn J Clin Oncol. 2023;53:253-262.
    PubMed         Abstract available
    
    

    
    Lab Invest

58. IZAWA M, Tanaka N, Murakami T, Anno T, et al
    Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor Immune Microenvironment and Reflects the Prognosis of Bladder Cancer.
    Lab Invest. 2023;103:100040.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

59. WU S, Hong G, Xu A, Zeng H, et al
    Artificial intelligence-based model for lymph node metastases detection on whole slide images in bladder cancer: a retrospective, multicentre, diagnostic study.
    Lancet Oncol. 2023 Mar 6:S1470-2045(23)00061.
    PubMed         Abstract available
    
    

    
    Med Clin (Barc)

60. MATUTE GUERRERO A, Abanses Moreno P, Villasmil Chaparro I
    Pulmonary thrombotic microangiopathy caused by neoplastic urothelial carcinoma cells.
    Med Clin (Barc). 2023;160:226-227.
    PubMed        
    
    

    
    Med Lett Drugs Ther

61. 
    In brief: Adstiladrin - a gene therapy for bladder cancer.
    Med Lett Drugs Ther. 2023;65:e40-e41.
    PubMed        
    
    

    
    Med Oncol

62. JIN D, Qian L, Xia J, Zhang R, et al
    In vivo detection of circulating tumor cells predicts high-risk features in patients with bladder cancer.
    Med Oncol. 2023;40:113.
    PubMed         Abstract available
    
    

    
    Nihon Ronen Igakkai Zasshi

63. YAMADA Y, Kume H
    [Frailty and surgical tolerability in elderly patients undergoing robot-assisted radical cystectomy (RARC)].
    Nihon Ronen Igakkai Zasshi. 2023;60:38-42.
    PubMed         Abstract available
    
    

    
    Nucleus

64. SCHMOKEL SS, Nordentoft I, Lindskrog SV, Lamy P, et al
    Improved protocol for single-nucleus RNA-sequencing of frozen human bladder tumor biopsies.
    Nucleus. 2023;14:2186686.
    PubMed         Abstract available
    
    

    
    Oncogene

65. SUN J, Zhang H, Wei W, Xiao X, et al
    Regulation of CD8(+) T cells infiltration and immunotherapy by circMGA/HNRNPL complex in bladder cancer.
    Oncogene. 2023 Mar 3. doi: 10.1038/s41388-023-02637.
    PubMed         Abstract available
    
    

    
    Pharmacoeconomics

66. MANDRIK O, Hahn AI, Catto JWF, Zauber AG, et al
    Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review.
    Pharmacoeconomics. 2023 Mar 8. doi: 10.1007/s40273-023-01256.
    PubMed         Abstract available
    
    

    
    PLoS One

67. LIU CL, Tsai HW, Peng SL, Chang CP, et al
    CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma.
    PLoS One. 2023;18:e0281873.
    PubMed         Abstract available
    
    

    
    Prog Urol

68. GABRIEL PE, Pinar U, Parra J, Vaessen C, et al
    [Pathological pelvic lymph node involvement in muscle-invasive bladder cancer patients treated with radical cystectomy: A narrative review].
    Prog Urol. 2023;33:145-154.
    PubMed         Abstract available
    
    

    
    Sci Rep

69. CH'NG ES
    Mining The Cancer Genome Atlas gene expression data for lineage markers in distinguishing bladder urothelial carcinoma and prostate adenocarcinoma.
    Sci Rep. 2021;11:6765.
    PubMed         Abstract available
    
    
70. LEE YS, Ha MS, Tae JH, Chang IH, et al
    Gemcitabine-cisplatin versus MVAC chemotherapy for urothelial carcinoma: a nationwide cohort study.
    Sci Rep. 2023;13:3682.
    PubMed         Abstract available
    
    

    
    Urol Oncol

71. WOLDU SL, Labbate C, Murray KS, Rose K, et al
    Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
    Urol Oncol. 2023;41:147.
    PubMed         Abstract available
    
    
72. BARLETTA F, Tappero S, Panunzio A, Incesu RB, et al
    Conditional survival after radical cystectomy for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder: A population-based analysis.
    Urol Oncol. 2023;41:147.
    PubMed         Abstract available
    
    
73. GERALD T, Margulis V, Meng X, Bagrodia A, et al
    Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients.
    Urol Oncol. 2023;41:148.
    PubMed         Abstract available
    
    
74. LI KD, Chu CE, Patel M, Meng MV, et al
    Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer.
    Urol Oncol. 2023 Mar 1:S1078-1439(23)00009-1. doi: 10.1016/j.urolonc.2023.
    PubMed         Abstract available
    
    
75. TAPPERO S, Barletta F, Piccinelli ML, Cano Garcia C, et al
    Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer.
    Urol Oncol. 2023 Mar 5:S1078-1439(23)00015-7. doi: 10.1016/j.urolonc.2023.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: